Articles for category: Most Popular

The whipping post

Most Popular

Investing Insights Post-Fed Rate Cut Unlocking Opportunities: Navigating the Post-Fed Rate Cut Terrain

In a pivotal move on Wednesday, the Federal Reserve opted for an outsized 50-basis point rate cut, a decision typically reserved for times of economic turmoil. Fed Chair Jerome Powell’s strategic shift in policy focus from inflation to the labor market set tongues wagging in financial circles. The central bank’s forward guidance signals a path ...

The whipping post

Most Popular

Evaluating Amazon.com, Inc.’s Attractive Investment Potential

Amazon (AMZN) recently grabbed investors’ attention as one of the most searched stocks on Zacks.com. Exploring the critical factors that can impact its performance in the near future is imperative for savvy investors. Over the past month, this online retail giant’s shares surged by +7.8%, surpassing the Zacks S&P 500 composite’s +2.1% change. Within the ...

The whipping post

Most Popular

Vanda Pharmaceuticals Faces Setback as FDA Rejects NDA for Tradipitant in Gastroparesis Vanda Pharmaceuticals Faces Setback as FDA Rejects NDA for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Inc. VNDA recently experienced a dip in its stock price after receiving a complete response letter from the FDA regarding its new drug application (NDA) for tradipitant, a potential treatment for gastroparesis. The announcement led to a 6.1% decrease in the company’s shares on Sept. 19, highlighting the regulatory setback. Gastroparesis, characterized by ...

The whipping post

Most Popular

Deciphering Apple Vs. Microsoft Battle: Impact of $35B Rebalance on Bullish Momentum Deciphering Apple Vs. Microsoft Battle: Impact of $35B Rebalance on Bullish Momentum

Apple Inc AAPL investors are on the edge anticipating a seismic shift as quarterly market index fund rebalancing coincides with a rare trifecta event – a recipe for heightened market tumult. Unprecedented Rebalancing Spurs Apple’s Rise Amidst $250 billion in stock readjustments, the iPhone behemoth emerges as a primary beneficiary. An significant change emanates from ...

The whipping post

Most Popular

Unveiling the AI Treasure Trove Amidst Lower Interest Rates Unveiling the AI Treasure Trove Amidst Lower Interest Rates

The Federal Reserve’s recent aggressive interest rate adjustment signals a potential boon for investors in artificial intelligence (AI) technology giants like NVIDIA Corporation, Microsoft Corporation, and Micron Technology, Inc. As the Fed slashes rates, borrowing costs for these tech players decrease, amplifying profit margins and sustaining cash flows required for growth endeavors. Amidst the relentless ...

The whipping post

Most Popular

Assessing Intel Stock: A Deep Dive into the Foundry Spinoff Plans Assessing Intel Stock: A Deep Dive into the Foundry Spinoff Plans

While the broader Dow Jones Industrial Average is reaching new heights, semiconductor giant Intel (INTC) is grappling with a significant downturn. The tech company’s stock has plummeted by 70% from its peak, marking a steep decline of nearly 58% in 2024. With a market capitalization of $88.4 billion, it is now crucial to evaluate whether ...

The whipping post

Most Popular

2 Soaring Growth Stocks I'd Buy and Hold Forever

The artificial intelligence (AI) space is growing rapidly, with predictions that the AI market could reach trillions of dollars in value over the next decade. AI is transforming industries such as healthcare, retail, manufacturing, technology, finance, and more, by automating processes and unlocking new levels of productivity. Growth stocks, and particularly those in the AI space, ...

The whipping post

Most Popular

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Allarity Therapeutics, Inc. (ALLR) Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ALLR securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). Allarity investors have ...